SNTI vs. PMCB, TCON, BCLI, AIM, ACOR, APTO, ZIVO, SQZ, EVAX, and SABS
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include PharmaCyte Biotech (PMCB), TRACON Pharmaceuticals (TCON), Brainstorm Cell Therapeutics (BCLI), AIM ImmunoTech (AIM), Acorda Therapeutics (ACOR), Aptose Biosciences (APTO), ZIVO Bioscience (ZIVO), SQZ Biotechnologies (SQZ), Evaxion Biotech A/S (EVAX), and SAB Biotherapeutics (SABS). These companies are all part of the "biological products, except diagnostic" industry.
PharmaCyte Biotech (NASDAQ:PMCB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
PharmaCyte Biotech has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500.
In the previous week, PharmaCyte Biotech and PharmaCyte Biotech both had 4 articles in the media. Senti Biosciences' average media sentiment score of 0.72 beat PharmaCyte Biotech's score of 0.72 indicating that PharmaCyte Biotech is being referred to more favorably in the media.
PharmaCyte Biotech has a net margin of 0.00% compared to PharmaCyte Biotech's net margin of -2,692.82%. Senti Biosciences' return on equity of -9.69% beat PharmaCyte Biotech's return on equity.
PharmaCyte Biotech has higher earnings, but lower revenue than Senti Biosciences. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Senti Biosciences has a consensus price target of $6.00, indicating a potential upside of 1,491.09%. Given PharmaCyte Biotech's higher possible upside, analysts clearly believe Senti Biosciences is more favorable than PharmaCyte Biotech.
34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by company insiders. Comparatively, 12.5% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Senti Biosciences received 3 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
Summary
PharmaCyte Biotech and Senti Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Senti Biosciences Competitors List
Related Companies and Tools